KWGN Anchor Chris Parente Resigns Amid Cancer Treatment
The veteran broadcaster is leaving his role at the Denver station to prioritize his ongoing health recovery.
Updated on Oct. 15, 2026 in Cancer
Chris Parente has stepped down from his position as an anchor at KWGN after seven years with the station. The seven-time Emmy winner is currently undergoing treatment for bladder cancer, a journey that began following a diagnosis in 2025.
Why it matters
Side effects from cancer treatment, including persistent fatigue and pain, have made the physical demands of live television hosting increasingly difficult. Parente is stepping away to focus entirely on his medical recovery regimen.
Parente is undergoing bacillus Calmette-Guérin immunotherapy and chemotherapy delivered directly into the bladder to treat his condition. His medical treatment regimen is currently expected to continue through February 2027.
The players
Chris Parente
He is an award-winning television broadcaster who most recently served as an anchor for the Denver-based station KWGN.
KWGN
This is a Denver-based television station where Parente worked as an anchor and host of the morning program Daybreak.
The details
Parente first discovered symptoms of his illness in October 2025, with a CT scan confirming the presence of a bladder tumor five days later. Before his time at KWGN, he built a career spanning television markets in Indiana and Kentucky.
Timeline
October 11, 2025: Parente first noticed symptoms of his illness.
October 16, 2025: A CT scan revealed a tumor in Parente's bladder.
2019: Parente became host of the KWGN program Daybreak.
October 12, 2026: Parente delivered his final broadcast for KWGN.
February 2027: Expected completion of Parente's current medical treatment regimen.
The Big Picture
Parente's medical care follows the standard clinical pattern established by the FDA-approved bacillus Calmette-Guérin immunotherapy protocol. His transition out of public media reflects the broader necessity for patients to manage chronic treatment requirements alongside high-pressure careers.
Parente's experience highlights the challenges of balancing intensive immunotherapy and chemotherapy with professional duties. His departure underscores how specific treatment side effects like chronic fatigue often necessitate significant lifestyle changes for patients.
The takeaway
Patients managing bladder cancer often find that recovery requires a full-time commitment to treatment schedules. Prioritizing rest during intensive immunotherapy is a common necessity for maintaining long-term health outcomes.
What happens next
Parente's current medical treatment regimen is scheduled to continue through February 2027, when he may provide further updates on his health status.
Further reading
For more information on current treatment trends, see the latest updates on the Cancer section.
Source note: This article includes information reported by NewscastStudio.
